Terms: = Leukemia AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Clinical Outcome
18 results:
1. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract] [Full Text] [Related]
2. Involvement of AF1q/MLLT11 in the progression of ovarian cancer.
Tiberio P; Lozneanu L; Angeloni V; Cavadini E; Pinciroli P; Callari M; Carcangiu ML; Lorusso D; Raspagliesi F; Pala V; Daidone MG; Appierto V
Oncotarget; 2017 Apr; 8(14):23246-23264. PubMed ID: 28423573
[TBL] [Abstract] [Full Text] [Related]
3. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract] [Full Text] [Related]
4. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract] [Full Text] [Related]
5. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-erk signaling in CLL.
Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
[TBL] [Abstract] [Full Text] [Related]
6. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response.
Bologna C; Buonincontri R; Serra S; Vaisitti T; Audrito V; Brusa D; Pagnani A; Coscia M; D'Arena G; Mereu E; Piva R; Furman RR; Rossi D; Gaidano G; Terhorst C; Deaglio S
J Clin Invest; 2016 Jan; 126(1):181-94. PubMed ID: 26619119
[TBL] [Abstract] [Full Text] [Related]
7. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches.
D'Angelo V; Iannotta A; Ramaglia M; Lombardi A; Zarone MR; Desiderio V; Affinita MC; Pecoraro G; Di Martino M; Indolfi P; Casale F; Caraglia M
J Exp Clin Cancer Res; 2015 Aug; 34(1):83. PubMed ID: 26268310
[TBL] [Abstract] [Full Text] [Related]
8. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
[TBL] [Abstract] [Full Text] [Related]
10. Deregulated MIR335 that targets mapk1 is implicated in poor outcome of paediatric acute lymphoblastic leukaemia.
Yan J; Jiang N; Huang G; Tay JL; Lin B; Bi C; Koh GS; Li Z; Tan J; Chung TH; Lu Y; Ariffin H; Kham SK; Yeoh AE; Chng WJ
Br J Haematol; 2013 Oct; 163(1):93-103. PubMed ID: 23888996
[TBL] [Abstract] [Full Text] [Related]
11. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
[TBL] [Abstract] [Full Text] [Related]
12. Divergence in CD19-mediated signaling unfolds intraclonal diversity in chronic lymphocytic leukemia, which correlates with disease progression.
Herishanu Y; Kay S; Dezorella N; Baron S; Hazan-Halevy I; Porat Z; Trestman S; Perry C; Braunstein R; Deutsch V; Polliack A; Naparstek E; Katz BZ
J Immunol; 2013 Jan; 190(2):784-93. PubMed ID: 23241880
[TBL] [Abstract] [Full Text] [Related]
13. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
Cesano A; Perbellini O; Evensen E; Chu CC; Cioffi F; Ptacek J; Damle RN; Chignola R; Cordeiro J; Yan XJ; Hawtin RE; Nichele I; Ware JR; Cavallini C; Lovato O; Zanotti R; Rai KR; Chiorazzi N; Pizzolo G; Scupoli MT
Haematologica; 2013 Apr; 98(4):626-34. PubMed ID: 23144194
[TBL] [Abstract] [Full Text] [Related]
14. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract] [Full Text] [Related]
15. A pathobiological role of the insulin receptor in chronic lymphocytic leukemia.
Saiya-Cork K; Collins R; Parkin B; Ouillette P; Kuizon E; Kujawski L; Erba H; Campagnaro E; Shedden K; Kaminski M; Malek SN
Clin Cancer Res; 2011 May; 17(9):2679-92. PubMed ID: 21307146
[TBL] [Abstract] [Full Text] [Related]
16. [p38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
He L; Li D; Hou KZ; Liu YP
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
[TBL] [Abstract] [Full Text] [Related]
17. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling.
Vey N; Mozziconacci MJ; Groulet-Martinec A; Debono S; Finetti P; Carbuccia N; Beillard E; Devilard E; Arnoulet C; Coso D; Sainty D; Xerri L; Stoppa AM; Lafage-Pochitaloff M; Nguyen C; Houlgatte R; Blaise D; Maraninchi D; Birg F; Birnbaum D; Bertucci F
Oncogene; 2004 Dec; 23(58):9381-91. PubMed ID: 15543237
[TBL] [Abstract] [Full Text] [Related]
18. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract] [Full Text] [Related]
